.
Sigma Pharmaceutical Limited (ASX:SIP) has generated a first half net profit of $16.3 million despite difficult trading conditions and flat growth in the Pharmaceutical Benefits Scheme.
The result marked a 37 per cent drop in the six months ended July 31, 2013, compared with $26.1 million in the previous corresponding period.
Sales revenue rose 3.1 per cent to $1.46 billion.
Sigma says it continues to operate in a challenging environment but will look to the new Federal Government to provide greater certainty in the sector.
The group declared an interim dividend of two cents per share, fully franked.
- Forums
- ASX - By Stock
- SIP
- News: Sigma posts profit, despite challenges
News: Sigma posts profit, despite challenges
Featured News
Add SIP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online